Cover Image

“The drug development pipeline for glioblastoma: a cross sectional assessment of the FDA Orphan Drug Product designation database”

Show other versions (1)

Background Glioblastoma multiforme (GBM) is the most common malignant brain tumor among adult patients and represents an almost universally fatal disease. Novel therapies for GBM are being developed under the orphan drug legislation and the knowledge on the molecular makeup of this disease has been...

Full description

Saved in:
Bibliographic Details
Main Authors: Johann, Pascal-David (Author) , Lenz, Dominic (Author) , Ries, Markus (Author)
Format: Article (Journal) Chapter/Article
Language:English
Published: January 04, 2021
In: medRxiv
Year: 2021, Pages: 1-21
DOI:10.1101/2021.01.01.21249120
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1101/2021.01.01.21249120
Verlag, kostenfrei, Volltext: https://www.medrxiv.org/content/10.1101/2021.01.01.21249120v1
Get full text
Author Notes:Pascal Johann MD, Dominic Lenz MD, Markus Ries MD PhD
Search Result 1
Cover Image

The drug development pipeline for glioblastoma: a cross sectional assessment of the FDA Orphan Drug Product designation database by Johann, Pascal-David (Author) , Lenz, Dominic (Author) , Ries, Markus (Author) ,


Get full text
Article (Journal) Online Resource

Saved in:
Show all versions (2)

Similar Items